p.93 抽出テキスト

controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:f40–f49. https://doi.org/ 10.1093/ehjcvp/pvaa120 630. Fitzmaurice DA, Hobbs FR, Jowett S, Mant J, Murray ET, Holder R, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383. https://doi.org/10.1136/bmj.39280. 660567.55 631. Pallisgaard JL, Schjerning A-M, Lindhardt TB, Procida K, Hansen ML, Torp-Pedersen C, et al. Risk of atrial fibrillation in diabetes mellitus: a nationwide cohort study. Eur J Prev Cardiol 2016;23:621–627. https://doi.org/10.1177/2047487315599892 632. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA 1994;271:840–844. https://doi.org/10.1001/jama.1994.03510350050036 633. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial fibrillation. Thromb Haemost 2013;110:213–222. https://doi.org/10.1160/TH13-02- 0165 634. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. Circulation 2013; 127:930–937. https://doi.org/10.1161/CIRCULATIONAHA.112.126656 635. Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021;398:1498–1506. https://doi.org/10.1016/S0140-6736(21)01637-8 636. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857–867. https://doi.org/10.7326/0003-4819-146-12-200706190-00007 637. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383: 955–962. https://doi.org/10.1016/S0140-6736(13)62343-0 638. Nielsen PB, Larsen TB, Skjøth F, Overvad TF, Lip GY. Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: a nationwide cohort study. Sci Rep 2016;6:27410. https://doi.org/10.1038/srep27410 639. Fauchier L, Clementy N, Bisson A, Ivanes F, Angoulvant D, Babuty D, et al. Should atrial fibrillation patients with only 1 nongender-related CHA2DS2-VASc risk factor be anticoagulated? Stroke 2016;47:1831–1836. https://doi.org/10.1161/STROKEAHA.116. 013253 640. Shin SY, Han S-J, Kim J-S, Im SI, Shim J, Ahn J, et al. Identification of markers associated with development of stroke in “clinically low-risk” atrial fibrillation patients. J Am Heart Assoc 2019;8:e012697. https://doi.org/10.1161/JAHA.119.012697 641. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093–1100. https://doi.org/10.1378/ chest.10-0134 642. Borre ED, Goode A, Raitz G, Shah B, Lowenstern A, Chatterjee R, et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018;118:2171–2187. https://doi.org/10.1055/s- 0038-1675400 643. Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, et al. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis. J Thromb Haemost 2020;18:791–801. https://doi.org/10.1111/ jth.14692 644. Jouven X, Lemaître RN, Rea TD, Sotoodehnia N, Empana J-P, Siscovick DS. Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005;26:2142–2147. https:// doi.org/10.1093/eurheartj/ehi376 645. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, et al. Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Diabetol 2010;47:161–168. https://doi.org/10.1007/s00592- 009-0157-9 646. Eranti A, Kerola T, Aro AL, Tikkanen JT, Rissanen HA, Anttonen O, et al. Diabetes, glucose tolerance, and the risk of sudden cardiac death. BMC Cardiovasc Disord 2016;16:51. https://doi.org/10.1186/s12872-016-0231-5 647. Zaccardi F, Khan H, Laukkanen JA. Diabetes mellitus and risk of sudden cardiac death: a systematic review and meta-analysis. Int J Cardiol 2014;177:535–537. https://doi.org/ 10.1016/j.ijcard.2014.08.105 648. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998;136:205–212. https://doi.org/10.1053/hj.1998.v136.90226 649. Chen-Scarabelli C, Scarabelli TM. Suboptimal glycemic control, independently of QT interval duration, is associated with increased risk of ventricular arrhythmias in a highrisk population. Pacing Clin Electrophysiol 2006;29:9–14. https://doi.org/10.1111/j.1540- 8159.2006.00298.x 650. Secrest A, Becker D, Kelsey S, Laporte R, Orchard T. Characterizing sudden death and dead-in-bed syndrome in type 1 diabetes: analysis from two childhood-onset type 1 diabetes registries. Diabet Med 2011;28:293–300. https://doi.org/10.1111/j.1464- 5491.2010.03154.x 651. Tanenberg RJ, Newton CA, Drake AJ III. Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system. Endocr Pract 2010;16:244–248. https://doi.org/10.4158/EP09260.CR 652. NICE-Sugar Study Investigators. Hypoglycemia and risk of death in critically ill patients. N Engl J Med 2012;367:1108–1118. https://doi.org/10.1056/NEJMoa1204942 653. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818–828. https://doi.org/10.1056/NEJMoa1006524 654. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–2559. https://doi.org/10.1056/NEJMoa0802743 655. Laurita KR, Khan S, McMahon T, Dennis AT, Li V, Gaivin R, et al. Ventricular arrhythmias in mouse models of diabetic kidney disease. Sci Rep 2021;11:20570. https://doi. org/10.1038/s41598-021-99891-9 656. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, et al. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014;63:1738–1747. https://doi.org/10.2337/db13-0468 657. Hay L, Wilmshurst E, Fulcher G. Unrecognized hypo- and hyperglycemia in wellcontrolled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diab Technol Therap 2003;5:19–26. https://doi.org/10.1089/152091503 763816427 658. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) endorsed by: association for European Paediatric and Congenital Cardiology (AEPC). Europace 2015;17:1601–1687. https:// doi.org/10.1093/europace/euv319 659. Ruwald MH, Zareba W, Jons C, Zhang C, Ruwald A-CH, Olshansky B, et al. Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverterdefibrillator therapy and mortality in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) Trial. Circulation 2013;128:694–701. https://doi.org/10.1161/CIRCULATIONAHA.113.002472 660. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications 2003;17:169–178. https://doi.org/10.1016/S1056-8727(02) 00206-4 661. Kobayashi S, Nagao M, Asai A, Fukuda I, Oikawa S, Sugihara H. Severity and multiplicity of microvascular complications are associated with QT interval prolongation in patients with type 2 diabetes. J Diabetes Invest 2018;9:946–951. https://doi.org/10. 1111/jdi.12772 662. Molon G, Costa A, Bertolini L, Zenari L, Arcaro G, Barbieri E, et al. Relationship between abnormal microvolt T-wave alternans and poor glycemic control in type 2 diabetic patients. Pacing Clin Electrophysiol 2007;30:1267–1272. https://doi.org/10.1111/j. 1540-8159.2007.00849.x 663. O’Brien I, O’Hare J, Lewin I, Corrall R. The prevalence of autonomic neuropathy in insulin-dependent diabetes mellitus: a controlled study based on heart rate variability. Q J Med 1986;61:957–967. https://doi.org/10.1093/oxfordjournals.qjmed.a068054 664. Tsuji H, Venditti Jr FJ, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation 1994;90:878–883. https://doi.org/10.1161/01.cir.90.2.878 665. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007; 115:387–397. https://doi.org/10.1161/CIRCULATIONAHA.106.634949 666. Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28. https://doi.org/ 10.1186/1475-2840-13-28 667. Balcıoğlu S, Arslan U, Türkoğlu S, Özdemir M, Çengel A. Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy. Am J Cardiol 2007;100:890–893. https://doi.org/10.1016/j. amjcard.2007.03.106 668. Bissinger A, Ruxer J, Ahmed RB, Lubinski A. Heart rate turbulence in patients with poorly controlled diabetes mellitus type 2. Arch Med Sci 2014;10:1073–1077. https:// doi.org/10.5114/aoms.2014.47819 669. Kuppermann N, Park J, Glatter K, Marcin JP, Glaser NS. Prolonged QT interval corrected for heart rate during diabetic ketoacidosis in children. Arch Pediatr Adolesc Med 2008;162:544–549. https://doi.org/10.1001/archpedi.162.6.544 670. Murphy N, Ford-Adams M, Ong K, Harris N, Keane S, Davies C, et al. Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. Diabetologia 2004;47:1940–1947. https://doi.org/10. 1007/s00125-004-1552-y 671. Ninkovic VM, Ninkovic SM, Miloradovic V, Stanojevic D, Babic M, Giga V, et al. Prevalence and risk factors for prolonged QT interval and QT dispersion in patients with type 2 diabetes. Acta Diabetol 2016;53:737–744. https://doi.org/10.1007/ s00592-016-0864-y

ESC Guidelines                                                                                                                                                                                          4135

Downloaded from academic.oup.com/eurheartj/article/44/39/4043/7238227 by guest on 07 October 2026